Shanghai Labway Clinical Laboratory Past Earnings Performance
Past criteria checks 0/6
Shanghai Labway Clinical Laboratory's earnings have been declining at an average annual rate of -25.4%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 9.4% per year.
Key information
-25.4%
Earnings growth rate
-26.6%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 9.4% |
| Return on equity | -10.7% |
| Net Margin | -10.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Labway Clinical Laboratory makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,725 | -181 | 384 | 61 |
| 30 Jun 24 | 1,725 | -124 | 458 | 59 |
| 31 Mar 24 | 1,698 | -162 | 416 | 48 |
| 31 Dec 23 | 1,674 | -142 | 433 | 49 |
| 30 Sep 23 | 2,360 | 12 | 462 | 94 |
| 30 Jun 23 | 2,977 | 185 | 430 | 97 |
| 31 Mar 23 | 3,784 | 461 | 587 | 108 |
| 01 Jan 23 | 4,199 | 617 | 595 | 109 |
| 30 Sep 22 | 3,613 | 631 | 533 | 65 |
| 30 Jun 22 | 3,068 | 536 | 496 | 56 |
| 31 Mar 22 | 2,250 | 328 | 385 | 46 |
| 01 Jan 22 | 1,778 | 204 | 334 | 39 |
| 30 Sep 21 | 1,649 | 195 | 291 | 29 |
| 30 Jun 21 | 1,509 | 162 | 265 | 27 |
| 31 Mar 21 | 1,435 | 165 | 269 | 28 |
| 31 Dec 20 | 1,238 | 110 | 211 | 22 |
| 31 Dec 19 | 1,153 | 92 | 208 | 19 |
| 31 Dec 18 | 1,053 | 73 | 206 | 17 |
| 31 Dec 17 | 923 | 6 | 261 | 14 |
| 30 Jun 17 | 974 | 60 | 207 | 0 |
| 31 Mar 17 | 889 | 59 | 192 | 0 |
| 31 Dec 16 | 805 | 59 | 176 | 0 |
| 30 Sep 16 | 744 | 78 | 148 | 0 |
| 30 Jun 16 | 684 | 96 | 120 | 0 |
| 31 Mar 16 | 646 | 89 | 107 | 0 |
| 31 Dec 15 | 608 | 82 | 94 | 0 |
| 31 Dec 14 | 541 | 70 | 66 | 0 |
Quality Earnings: 301060 is currently unprofitable.
Growing Profit Margin: 301060 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301060 is unprofitable, and losses have increased over the past 5 years at a rate of 25.4% per year.
Accelerating Growth: Unable to compare 301060's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 301060 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-5.7%).
Return on Equity
High ROE: 301060 has a negative Return on Equity (-10.75%), as it is currently unprofitable.